LV15503A - 2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer - Google Patents

2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer

Info

Publication number
LV15503A
LV15503A LVP-18-108A LV180108A LV15503A LV 15503 A LV15503 A LV 15503A LV 180108 A LV180108 A LV 180108A LV 15503 A LV15503 A LV 15503A
Authority
LV
Latvia
Prior art keywords
selenopheno
cancer
prevention
treatment
chromenes
Prior art date
Application number
LVP-18-108A
Other languages
Latvian (lv)
Inventor
Pavels Arsenjans
Ilona Domračeva
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-18-108A priority Critical patent/LV15503A/en
Publication of LV15503A publication Critical patent/LV15503A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to 2H-selenopheno[3,2-h]chromene derivatives and pharmaceutical compositions comprising the same for use in prevention and treatment of cancer.
LVP-18-108A 2018-12-12 2018-12-12 2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer LV15503A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-18-108A LV15503A (en) 2018-12-12 2018-12-12 2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-18-108A LV15503A (en) 2018-12-12 2018-12-12 2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
LV15503A true LV15503A (en) 2020-06-20

Family

ID=65324507

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-18-108A LV15503A (en) 2018-12-12 2018-12-12 2h-selenopheno[3,2-h]chromenes for prevention and treatment of cancer

Country Status (1)

Country Link
LV (1) LV15503A (en)

Similar Documents

Publication Publication Date Title
MY197635A (en) Benzooxazole derivatives as immunomodulators
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2022005780A (en) Estrogen receptor modulators.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MY201925A (en) Macrocyclic compounds and uses thereof
MX2018005019A (en) Benzofuran derivative, preparation method thereof and use thereof in medicine.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX2022007155A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof.
TR201901077T4 (en) Combined Preparations for Cancer or Infection Treatment
MX2018009870A (en) Taf1 inhibitors for the therapy of cancer.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
AU2018380132A8 (en) Tubulin inhibitors
EP4275759A3 (en) Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
MX2020000135A (en) New quinolinone compounds.
AU2017272405A1 (en) Imidazolone compounds as human Neutrophil Elastase inhibitors
UA120083C2 (en) ANTIMETASTATIC 2H-SELENOPHENO[3,2-h]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019008603A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease.